Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27879609 | 0.86 | GAA (0.39) | ATRMAPKAPK2MAP4K4TRPA1STK17B | |
| SCHEMBL1699239 | 0.85 | ATR (0.46) | ATRMAPKAPK2METAP1HSP90AA1HSP90AB1 | |
| SCHEMBL28705728 | 0.84 | ATR (0.45) | ATRMAPKAPK2METAP1HSP90AA1HSP90AB1 | |
| SCHEMBL12321293 | 0.84 | MAP4K4 (0.40) | ATRMAPKAPK2MAP4K4METAP1BRD9 | |
| SCHEMBL29759682 | 0.84 | MAP4K4 (0.40) | ATRMAPKAPK2MAP4K4METAP1BRD9 | |
| SCHEMBL380261 | 0.83 | AAK1 (0.45) | ATRMAPKAPK2METAP1HSP90AA1HSP90AB1 | |
| SCHEMBL15223288 | 0.83 | ATR (0.44) | ATRMAPKAPK2METAP1HSP90AA1HSP90AB1 | |
| SCHEMBL28708582 | 0.82 | ATR (0.46) | ATRMAPKAPK2METAP1HSP90AA1HSP90AB1 | |
| SCHEMBL18961320 | 0.82 | ATR (0.43) | ATRMAPKAPK2METAP1HSP90AA1HSP90AB1 | |
| SCHEMBL29435550 | 0.81 | RXFP1 (0.46) | ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590098-B2 | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same | AXCESO BIOPHARMA CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-4215533-B1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AXCESO BIOPHARMA CO LTD (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-20230348474-A1 | PYRIMIDO PYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | AXCESO BIOPHARMA CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| EP-4215533-A1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Axceso Biopharma Co., Ltd. (KR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022060094-A1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 엑세쏘바이오파마 | 2022-03-24 | — | — | WO | disclosed |
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | ATR 982/4885MAPKAPK2 85/4885MAP4K4 146/4885 |
| US-20230348474-A1 | PYRIMIDO PYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PDCD1, PDCD1LG2, CD274 | ATR 383/4885MAPKAPK2 3330/4885MAP4K4 2916/4885 |
| US-12590098-B2 | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same | PDCD1, CD274, PDCD1LG2 | ATR 1179/4885MAPKAPK2 2830/4885MAP4K4 2413/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | ATR 982/4885MAPKAPK2 85/4885MAP4K4 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.